- Champignon Brands Selected as Headline Partner for Prohibition Partners’ Upcoming Virtual Psychedelics Symposium
- Following Wednesday’s Bullish Price Action, SHRM Stock Could Be in the Very Early Stages of Another Major Breakout
Champignon Brands (CSE: SHRM) (OTC: SHRMF) (FRA: 496) announced yesterday that it was selected as the headline partner for the Prohibition Partners LIVE ‘PSYCH: The Psychedelics Symposium‘ set to take place June 22 – 23, 2020.
The Psychedelics Symposium
PSYCH is an event designed to bring together key figures and investors that are at the forefront of the emerging psychedelics sector. Prohibition Partners LIVE is the architect of PSYCH, which will be this year’s most significant virtual psychedelics conference.
Event participants will have the opportunity to share unparalleled insights and intelligence with industry leaders from the world of healthcare, science and business. PSYCH will also feature presentations from experts who will share their latest findings and analysis on the state of the industry across the globe.
“While cannabis has paved much of the way for psychedelics in terms of legal progress and changing public perception, psychedelics as medicines are backed by a comparatively more powerful knowledge base. The potential for psychedelics in innovative treatments for numerous high-prevalence health problems has become the next major focus,” stated the company via press release.
“The impact of COVID-19 has put greater emphasis on the importance of mental health. Consumers are looking for options to improve their mental health, and, as the body of evidence mounts for psychedelics, the healthcare industry is responding with solutions. We’re delighted to partner with Champignon Brands on PSYCH and support their vision of improving mental health via psychedelics,” said Stephen Murphy, Managing Director of Prohibition Partners.
Champignon Brands is a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine. The company has quickly emerged as an industry leader and currently boasts an impressive portfolio of accretive assets that target vital segments of the medicinal psychedelics for mental health vertical. Champignon’s assets include:
Champignon Brands is inviting all of its current shareholders as well as prospective investors to join the company at PSYCH: The Psychedelics Symposium on June 22 – 23. Investors that are interested in learning more about psychedelics and the industry’s latest developments, this is your chance to hear directly from world-renowned speakers and network with industry-leading professionals.
PSYCH participants will have the opportunity to attend live-streamed keynotes and panels from over 150 CEOs, policymakers and cultural leaders, and gain unrivalled access to some of the most influential brands and businesses in the world as they discuss how cannabis and psychedelics will affect our future.
Learn More About PSYCH: The Psychedelics Symposium
SHRM Stock Price Action & Chart Update
Champignon Brands has, without a doubt, been the psychedelics sector’s top-performing stock in 2020. Since the company’s IPO on March 2, 2020, shares of Champignon’s CSE listed SHRM stock have soared as much as 387.18% on route to reaching its 52-week high of $0.95 in early April.
SHRM is currently up an impressive 335.9% YTD. By comparison, MindMed (NEO: MMED) (OTC: MMEDF) (FRA: BGHM), which IPO’d the day after Champignon and is backed by billionaire Kevin O’Leary and Canopy Growth (TSX: WEED) (NYSE: CGC) (FRA: 11L1) founder Bruce Linton, is only up 1.67% YTD.
For a visual reference, below is a chart comparison of Champignon Brands (CSE: SHRM) vs MindMed (NEO: MMED).
SHRM Breakout Could Already Be Underway
Those familiar with Technical Analysis and chart patterns will notice one very bullish aspect of the SHRM stock chart below. Following SHRM’s recent healthy pullback, the stock has been consolidating beautifully while forming another Bull Pennant chart formation. To see what transpired the last time SHRM formed a pennant chart pattern or to familiarize yourself with the significance of the formation, read our previous articles on the topic here and here.
SHRM officially broke through and closed above the upper resistance trendline of the pennant pattern after closing today’s training session at $0.85 per share. With SHRM now trading outside the pennant, the upper trendline, which previously served as resistance, should now serve as support.
Investors should be paying close attention to shares of Champignon Brands this week as we could be looking at the very early stages of another major SHRM breakout. If SHRM stock can hold its newly formed support line and volume continues to rise, it could be game on for the next leg higher.
Learn more about Champignon Brands: Website | IR Website | Investor Deck | Investor Group | SHRM Chart
Follow Champignon Brands on Social Media: Facebook | Instagram | Twitter
Also Read: These 2 Companies Are Turning LSD, Magic Mushrooms, Ketamine and MDMA into the Next Blockbuster Drugs
Canopy Growth Founder Bruce Linton and Billionaire “Mr. Wonderful” Kevin O’Leary from Shark Tank, Are Going All in on What They Think is a Much Bigger Opportunity Than the Cannabis Boom
Read More Psychedelic Profits Articles Here
Follow Psychedelic Profits on Social Media: Facebook | Twitter | LinkedIn | Investor Group
Did you enjoy this article? If so, sign up for our Email Newsletter below to start receiving our weekly recap of the week’s best articles.
The Most Anticipated U.S. MSO IPO of 2020 is Drawing Near
The Cannabis Sector is Long Overdue for a High-Profile IPO
The Wait is Nearly Over, TCI’s MSO IPO of 2020 is Almost Here
Get Your Copy of The Ultimate Cannabis Investing Guide
Join the Discussion in the TCI Investor Group
Champignon Brands is a paid client of The Cannabis Investor. The Cannabis Investor holds a position in Champignon Brands.
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.
Featured ArticlesCannabis Stock NewsCannabis Industry ArticlesTechnical Analysis ArticlesWatch Cannabis Stock Videos